STXS Quote, Financials, Valuation and Earnings

Electromed has a net margin of -118.53% compared to Stereotaxis's net margin of 12.11%. Stereotaxis's return on equity of -139.2% beat Electromed's return on equity of 15.91%.

Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 121.68%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 60.31%. Given that Stereotaxis has higher upside potential than Electromed, analysts believe Stereotaxis is more attractive than Electromed.

Stereotaxis has a beta of 1.602, which suggesting that the stock is 60.223% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Stereotaxis quarterly revenues are $6.3M, which are smaller than Electromed quarterly revenues of $16.3M. Stereotaxis's net income of -$7.5M is lower than Electromed's net income of $2M. Notably, Stereotaxis's price-to-earnings ratio is -- while Electromed's PE ratio is 30.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 6.42x versus 3.47x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of -118.53% compared to Stereotaxis's net margin of -16.69%. Stereotaxis's return on equity of -139.2% beat IRIDEX's return on equity of -157.91%.

Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 121.68%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 72.41%. Given that Stereotaxis has higher upside potential than IRIDEX, analysts believe Stereotaxis is more attractive than IRIDEX.

Stereotaxis has a beta of 1.602, which suggesting that the stock is 60.223% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.737, suggesting its less volatile than the S&P 500 by 26.316%.

Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Stereotaxis quarterly revenues are $6.3M, which are smaller than IRIDEX quarterly revenues of $11.6M. Stereotaxis's net income of -$7.5M is lower than IRIDEX's net income of -$1.9M. Notably, Stereotaxis's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 6.42x versus 0.39x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -118.53% compared to Stereotaxis's net margin of -2.16%. Stereotaxis's return on equity of -139.2% beat Myomo's return on equity of -48.64%.

Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 121.68%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 89.55%. Given that Stereotaxis has higher upside potential than Myomo, analysts believe Stereotaxis is more attractive than Myomo.

Stereotaxis has a beta of 1.602, which suggesting that the stock is 60.223% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.

Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Stereotaxis quarterly revenues are $6.3M, which are smaller than Myomo quarterly revenues of $12.1M. Stereotaxis's net income of -$7.5M is lower than Myomo's net income of -$260.1K. Notably, Stereotaxis's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 6.42x versus 5.66x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

TransMedics Group has a net margin of -118.53% compared to Stereotaxis's net margin of 5.64%. Stereotaxis's return on equity of -139.2% beat TransMedics Group's return on equity of 19.17%.

Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 121.68%. On the other hand TransMedics Group has an analysts' consensus of $103.14 which suggests that it could grow by 9.52%. Given that Stereotaxis has higher upside potential than TransMedics Group, analysts believe Stereotaxis is more attractive than TransMedics Group.

Stereotaxis has a beta of 1.602, which suggesting that the stock is 60.223% more volatile than S&P 500. In comparison TransMedics Group has a beta of 2.138, suggesting its more volatile than the S&P 500 by 113.849%.

Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. TransMedics Group pays out -- of its earnings as a dividend.

Stereotaxis quarterly revenues are $6.3M, which are smaller than TransMedics Group quarterly revenues of $121.6M. Stereotaxis's net income of -$7.5M is lower than TransMedics Group's net income of $6.9M. Notably, Stereotaxis's price-to-earnings ratio is -- while TransMedics Group's PE ratio is 93.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 6.42x versus 7.51x for TransMedics Group. Usually stocks with elevated PS ratios are considered overvalued.